Mass General Brigham Ventures, a venture fund established in 2008, is located in Cambridge. Specializing in healthcare and life sciences, they focus on Seed, Series A, and Series B stages of funding. Carl M. Berke is a partner at the firm, and their portfolio includes SwanBio Therapeutics. With 11 investments and 1 exit, Mass General Brigham Ventures actively supports innovative companies in the healthcare and life science sectors. For more information, visit their website at www.massgeneralbrighamventures.com.